Table 3.

Secondary results testing effects of the intervention on immediate post-program scores and on slopes of change in outcomes over all three assessments. Analyses include 68 participants who provided baseline and at least one follow-up score. Results presented include the F score, the degrees of freedom (df), significance level of the analysis (P), measures of effect size (eta² and Cohen's d), and observed power (1-β).

	Post-Program						Slopes
	F	df	P	Eta2*	d	1-β	F	df	P	Eta2*	d	1-β
Symptom Variables
PSS	14.60	52	.000	.22	.69	1.00	8.58	63	.005	.12	.58	.82
VAS	3.43	57	.057	.06	.48	.44	.83	64	.37	.01	.13	.15
SSQ	2.89	60	.094	.05	.20	.39	3.39	65	.07	.05	.43	.44
FSI	10.16	50	.002	.17	.73	.89	2.00	64	.16	.03	.34	.29
FIQ Symptom Severity	5.92	56	.018	.10	.58	.67	7.44	63	.008	.11	.69	.77
FIQ Physical Functioning	1.40	60	.241	.02	.04	.21	1.63	65	.21	.02	.39	24
Salivary Cortisol
Diurnal Mean	.39	61	.53	.01	.00	.10	.35	61	.56	.01	.19	.14
Diurnal Slope	.018	62	.90	.00	.18	.05	.76	61	.39	.01	1.5	.14
Mean Waking Value	.006	55	.938	.00	.02	.05	.288	65	.594	.01	.17	.08
CAR	1.60	51	.21	.03	.24	.24	.39	57	.54	.01	.67	.09
CAR Slope	1.03	52	.314	.02	.08	.17	.267	58	.607	.01	.03	.08

Note.

^*Eta² is the effect size indicating the proportion of the total variance attributed to the effect of treatment (calculated by dividing the sum-of-squares for an effect by the sum-of-squares total; small=.01, medium=.06, large=.14). PSS - Perceived Stress Scale, VAS - Visual Analog Scale, SSQ - Stanford Sleep Questionnaire, FSI - Fatigue Symptom Inventory, FIQ - Fibromyalgia Impact Questionnaire, CAR - cortisol awakening response